Senator Chuck Grassley is moving too slowly.
Earlier this year, I had the opportunity to meet with our U.S. Senator from Iowa to discuss medical cannabis. Sen. Grassley was receptive to hearing about how my 4-year-old son Abram, who suffers from an extremely rare genetic mutation that causes seizures, has been able to find relief from cannabidiol (CBD), a non-psychoactive cannabis oil that has allowed my son to live seizure-free for over a year. My son’s quality of life has greatly improved in the last year because of this and we have managed to cut by three-fourths his prescription for a highly addictive benzodiazepine — an FDA “approved” psychoactive drug that was never tested or approved specifically for children under the age of 18.
Recently, Sen. Grassley introduced the Cannabidiol Research Expansion Act which would ease research barriers and exempt pediatric patients with intractable epilepsy and their parents/legal guardians from the penalties of the Controlled Substances Act for the possession and pediatric use of CBD. Though Sen. Grassley is sympathetic to pediatric epilepsy patients, adult epilepsy patients and patients with conditions other than intractable epilepsy would be excluded under this legislation. In addition, no amounts of the chemical compound tetrahydrocannabinol (THC) are permitted. Though my son would be covered under this legislation, many other patients would be excluded and I worry where this type of legislation will lead us when our son is an adult and still in need of this medicine.
– Read the entire article at The Gazette.